Please provide your email address to receive an email when new articles are posted on . Myositis due to immune checkpoint therapy is rare yet severe, with more than half of patients developing ...

A series of case studies reveals the importance of early diagnosis and involvement of special teams of clinicians when dealing with potential cases of overlap syndrome, which encompasses myocarditis, ...

SOUTH SAN FRANCISCO, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced the opening of ...

The chimeric antigen receptor T-cell therapy (CAR T) from Cabaletta Bio has already been cleared for trials in systemic lupus erythematosus, myositis, and systemic sclerosis. “While we remain on track ...

New information about how to monitor medications given at home has been provided by the results of new research. Many autoimmune neuromuscular disorders, such as Myasthenia Gravis, myositis, and CIDP, ...

IND application for Descartes-08 in myositis accepted by FDA; seamless adaptive clinical trial offering potential opportunity for a single pivotal trial expected to commence in 1H26 Phase 1/2 ...

FREDERICK, Md., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, ...

– Phase 1/2 clinical trial evaluating CABA-201 in generalized myasthenia gravis features parallel cohort design and a starting dose consistent with the previously announced Phase 1/2 trials of ...

Please provide your email address to receive an email when new articles are posted on . Patients with myositis typically present with telltale muscle inflammation. However, properly identifying the ...

FREDERICK, Md., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, ...